Scientific work

Doç. Dr. Osman Köstek

197 publications. The source of the information is stated next to each publication.

Back to profile

  1. Which patients with colorectal cancer develop brain metastases? A multicenter analysis of clinical and molecular predictors.

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco.2026.44.2_suppl.218 Open-access full textSource: OpenAlex

  2. Clinicopathologic and molecular characteristics of colorectal cancer patients with brain metastases: a multicenter cohort study

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-69206-x Open-access full textSource: OpenAlex

  3. Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumab

    Immunotherapy, 2026

    DOI 10.1080/1750743x.2026.2662201 PMID 42011533 4 citations (Europe PMC) Open-access full textSource: OpenAlex

  4. Expression and prognostic importance of lymphocyte activation gene 3 and CD73 in advanced or metastatic hepatocellular carcinoma

    Journal of International Medical Research, 2026

    DOI 10.1177/03000605251386599 PMID 41521150 Open-access full textSource: OpenAlex

  5. Prevalence and Reactivation of Hepatitis B and C in Patients Undergoing Chemotherapy for Solid Tumors

    JCO Global Oncology, 2026

    DOI 10.1200/go-25-00234 PMID 41855443 Open-access full textSource: OpenAlex

  6. Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

    Current Oncology, 2026

    DOI 10.3390/curroncol33060365 PMID 42346265 Open-access full textSource: OpenAlex

  7. Predictors of Recurrence Following Curative-Intent Local Therapy for Oligometastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study from the Turkish Oncology Group (TOG)

    Eurasian Journal of Medical Investigation, 2026

    DOI 10.14744/ejmi.2612571 Source: ORCID

  8. Long-Term Outcomes and Conditional Recurrence-Free Survival in Stage II Colon Cancer: The Impact of Surveillance and Recurrence Detection Strategies

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15134901 PMID 42452362 Open-access full textSource: ORCID

  9. Prognostic Value of 18F-FDG PET/CT-Derived Secondary Lymphoid Organ Ratios and Hematologic Inflammation Markers in Advanced Non-Small Cell Lung Cancer Treated with Nivolumab

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15020798 PMID 41598735 Open-access full textSource: ORCID

  10. Prognostic Value of Systemic Immune-Inflammation Index in Mucosal Malignant Melanoma

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15020890 PMID 41598826 2 citations (Europe PMC) Open-access full textSource: ORCID

  11. Prognostic Value of Treatment-Related Body Composition Changes in Metastatic NSCLC Receiving Nivolumab

    Medicina, 2026

    DOI 10.3390/medicina62010098 PMID 41597384 1 citation (Europe PMC) Open-access full textSource: ORCID

  12. Tyrosine Kinase Inhibitor Therapy in Metastatic Medullary Thyroid Carcinoma: Real-World Data from Turkish Oncology Group

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15062353 PMID 41899277 Open-access full textSource: ORCID

  13. Abstract PS1-11-04: Her2-low expression is associated with inferior progression-free survival in hr-positive metastatic breast cancer treated with CDK4/6 inhibitors

    Clinical Cancer Research, 2026

    DOI 10.1158/1557-3265.sabcs25-ps1-11-04 Source: OpenAlex

  14. Vascular FDG Uptake on PET/CT in Patients Receiving Immune Checkpoint Inhibitors

    Journal of Oncological Sciences, 2026

    DOI 10.37047/jos.galenos.2026.2025-8-9 Open-access full textSource: OpenAlex

  15. Adult-Onset Diffuse Midline Glioma, H3K27-Altered: A Genomics-Guided, Individualized, Multimodal Treatment Approach

    Brain Sciences, 2026

    DOI 10.3390/brainsci16010097 PMID 41594818 Open-access full textSource: ORCID

  16. Drug-specific timing and fatality patterns of EGFR-TKI-associated interstitial lung disease in NSCLC-related JADER reports

    Naunyn-Schmiedeberg's archives of pharmacology, 2026

    DOI 10.1007/s00210-026-05751-6 PMID 42496703 Source: Europe PMC

  17. Circulating Tumor DNA-Based Assessment of Minimal Residual Disease in Colorectal Cancer: Prognostic and Predictive Implications

    Cancers, 2026

    DOI 10.3390/cancers18050754 PMID 41827689 2 citations (Europe PMC) Open-access full textSource: Europe PMC

  18. Development and internal validation of the CLIP-M score for advanced mucosal malignant melanoma: exploratory prognostic stratification and comparative assessment with the RMH score

    BMC cancer, 2026

    DOI 10.1186/s12885-026-16194-w PMID 42174513 Open-access full textSource: Europe PMC

  19. Integration of ımmunotherapy in limited-stage small cell lung cancer: a review of the literature

    Current Medical Research and Opinion, 2026

    DOI 10.1080/03007995.2026.2629092 PMID 41700432 3 citations (OpenAlex) Source: OpenAlex

  20. Acquired CD74–ROS1 fusion–mediated osimertinib resistance successfully treated with osimertinib and crizotinib: a case report

    Journal of Chemotherapy, 2026

    DOI 10.1080/1120009x.2026.2657116 PMID 41992733 2 citations (OpenAlex) Source: OpenAlex

  21. Efficacy and safety of sacituzumab govitecan in hormone receptor–positive metastatic breast cancer: A systematic review and meta-analysis

    Journal of Oncology Pharmacy Practice, 2026

    DOI 10.1177/10781552261462434 PMID 42317162 2 citations (OpenAlex) Source: OpenAlex

  22. Trastuzumab Deruxtecan–Induced Interstitial Lung Disease: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Evidence

    Cancer Control, 2026

    DOI 10.1177/10732748261451083 PMID 42104817 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  23. Capecitabine-induced pneumonitis: a rare case report and literature review

    Anti-Cancer Drugs, 2026

    DOI 10.1097/cad.0000000000001839 PMID 42668437 1 citation (OpenAlex) Source: OpenAlex

  24. Digital health engagement and health literacy among cancer patients: a cross-sectional study of ICT usage patterns

    BMC Health Services Research, 2026

    DOI 10.1186/s12913-026-15432-y 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  25. 132P Neutrophil–lymphocyte ratio as an independent prognostic marker in chondrosarcoma: A single-center cohort

    ESMO rare cancers., 2026

    DOI 10.1016/j.esmorc.2026.100338 Open-access full textSource: OpenAlex

  26. Oncological Perspective on Bone-Metastatic Colorectal Cancer: a Single-Centre Experience

    Journal of Gastrointestinal Cancer, 2026

    DOI 10.1007/s12029-026-01457-3 PMID 41944932 Source: OpenAlex

  27. Treatment Adherence and Quality of Life in Hypertensive Cancer Patients Receiving Chemotherapy

    Trends in pharmacy., 2026

    DOI 10.5152/trendspharm.2026.26001 Open-access full textSource: OpenAlex

  28. Comparative overall survival in T4N0 and T2-3N1 non-metastatic colon cancer: a retrospective cohort study

    Annals of Saudi Medicine, 2026

    DOI 10.5144/0256-4947.2026.169 PMID 42251515 Open-access full textSource: OpenAlex

  29. Prognostic Significance of Postoperative Edema in Surgically Treated Non-glioblastoma Diffuse Glioma

    Journal of Oncological Sciences, 2026

    DOI 10.37047/jos.galenos.2026.2026-2-2 Open-access full textSource: OpenAlex

  30. 622eP Claudin 18.2 expression in locally advanced and metastatic gastric adenocarcinoma: A single-center retrospective clinicopathological study

    Annals of Oncology, 2026

    DOI 10.1016/j.annonc.2026.05.661 Source: OpenAlex

  31. Baseline and Early On-Treatment Prognostic Nutritional Index in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer Treated with CDK4/6 Inhibitors

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15176790 PMID 42739793 Open-access full textSource: OpenAlex

  32. Prognostic Value of a Seven-Factor Risk Stratification System in T3N0 Colon Cancer: A Single-Center Retrospective Study

    Medicina, 2026

    DOI 10.3390/medicina62101846 PMID 42942377 Open-access full textSource: OpenAlex

  33. Healthy Lifestyle Behaviors and Health Literacy in Oncology Patients: Evaluation of Organic Food Consumption and Physical Activity

    Eurasian Journal of Medical Investigation, 2026

    DOI 10.14744/ejmi.269303 Source: OpenAlex

  34. Temporal Changes in Age at Diagnosis of Colorectal Cancer in Turkiye: A 9-Year Single-Center Analysis

    Eurasian Journal of Medical Investigation, 2026

    DOI 10.14744/ejmi.2612638 Source: OpenAlex

  35. Real-world plasma-based next-generation sequencing findings in metastatic lung adenocarcinoma: a single-center retrospective study

    Marmara medical journal, 2026

    DOI 10.5472/marumj.2070752 Open-access full textSource: OpenAlex

  36. Complete response to fourth-line nivolumab in metastatic hepatocellular carcinoma: A case report

    Marmara medical journal, 2026

    DOI 10.5472/marumj.2071755 Open-access full textSource: OpenAlex

  37. Assessing the Efficacy and Safety of Shorter versus Extended Adjuvant Treatment Duration for Stage III Low-Risk Colon Cancer: A Comparative Analysis

    Nigerian Journal of Clinical Practice, 2025

    DOI 10.4103/njcp.njcp_848_23 PMID 40326903 Open-access full textSource: OpenAlex

  38. Prognostic factors and outcomes of adjuvant and first-line metastatic treatments in melanoma a Turkish oncology group study

    Scientific Reports, 2025

    DOI 10.1038/s41598-025-87553-z PMID 39863702 Open-access full textSource: OpenAlex

  39. Sorafenib vs chemotherapy in the treatment of locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer: real-world data from Turkey

    Journal of Chemotherapy, 2025

    DOI 10.1080/1120009x.2024.2430845 PMID 39588941 1 citation (Europe PMC) Source: ORCID

  40. Efficacy of Second-Line Treatments After Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma and Related Prognostic Factors: A Multicenter Study by the Turkish Oncology Group (TOG)

    Turkish Journal of Gastroenterology, 2025

    DOI 10.5152/tjg.2025.24784 PMID 40241388 1 citation (Europe PMC) Open-access full textSource: ORCID

  41. Effects of neoadjuvant and adjuvant chemotherapy on survival in muscle-invasive bladder cancer: A multicenter study

    Turkish Journal of Clinics and Laboratory, 2025

    DOI 10.18663/tjcl.1575691 Open-access full textSource: ORCID

  42. Oncological perspective on Kaposi sarcoma: A single-centre experience

    Marmara Medical Journal, 2025

    DOI 10.5472/marumj.1627569 Open-access full textSource: ORCID

  43. Clinical and Demographic Features in Malignant Peritoneal Mesothelioma: Treatment Approaches and Factors Affecting Survival

    Journal of Oncological Sciences, 2025

    DOI 10.37047/jos.galenos.2025.2025-3-18 Open-access full textSource: OpenAlex

  44. Clinicopathological features and treatment outcomes of patients with fibrolamellar hepatocellular carcinoma: a retrospective multicenter study

    Annals of Saudi Medicine, 2025

    DOI 10.5144/0256-4947.2025.249 PMID 40753462 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  45. Prognostic Nutritional Index as a Biomarker in Metastatic Hormone-Sensitive Prostate Cancer: Impact on Survival and Treatment Optimization

    The Prostate, 2025

    DOI 10.1002/pros.24876 PMID 39972650 8 citations (Europe PMC) Open-access full textSource: Europe PMC

  46. Clinical Outcomes of CDK4/6 Inhibitor Therapy in HR+/HER2− Metastatic Breast Cancer: A Multicenter Comparison of HER2‐Low and HER2‐Zero Subgroups

    The Breast Journal, 2025

    DOI 10.1155/tbj/5577345 PMID 40620732 3 citations (OpenAlex) Open-access full textSource: OpenAlex

  47. Assessment of new pathological markers in early stage colon cancer: Insights and limitations

    World Journal of Gastrointestinal Oncology, 2025

    DOI 10.4251/wjgo.v17.i3.101325 PMID 40092924 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  48. Complete response after two cycles of enfortumab vedotin in a patient with metastatic bladder cancer: A case report

    Tumor Discovery, 2025

    DOI 10.36922/td025150026 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  49. Impact of Sarcopenia and Osteopenia on Prognosis in Metastatic Biliary Tract Cancer: A Single Center Experience

    Nutrition and Cancer, 2025

    DOI 10.1080/01635581.2025.2496371 PMID 40327413 1 citation (OpenAlex) Source: OpenAlex

  50. Does toxicity of cyclin-dependent kinase 4/6 inhibitor predict treatment response in metastatic hormone-positive breast cancer patients?

    Oncology in Clinical Practice, 2025

    DOI 10.5603/ocp.101970 Open-access full textSource: OpenAlex